	Application No.	Annlicentic
Notice of Allowability	Application No.	Applicant(s)
	09/711,476	CASKEY ET AL.
	Examiner	Art Unit
	Jeffrey Fredman	1637
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT F of the Office or upon petition by the applicant. See 37 CFR 1.31	S (OR REMAINS) CLOSED in 5) or other appropriate commu RIGHTS. This application is s	n this application. If not included unication will be mailed in due course. THIS
1. This communication is responsive to <u>July 11, 2005</u> .		
2. The allowed claim(s) is/are 42,54-62,64 and 65.		
3. \boxtimes The drawings filed on <u>10 December 2002</u> are accepted by	y the Examiner.	
 4. Acknowledgment is made of a claim for foreign priority to a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 		or (f).
		n No. 09/564 400
	•	
 Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). 		in this national stage application from the
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONI THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submin INFORMAL PATENT APPLICATION (PTO-152) which give the control of the	MENT of this application. mitted. Note the attached EXA ves reason(s) why the oath or list be submitted. Itson's Patent Drawing Review I's Amendment / Comment or 1.84(c)) should be written on the the header according to 37 CFI Disit of BIOLOGICAL MATE	MINER'S AMENDMENT or NOTICE OF declaration is deficient. (PTO-948) attached in the Office action of the drawings in the front (not the back) of R 1.121(d). ERIAL must be submitted. Note the
 Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/Paper No./Mail Date	6. Interview Su Paper No./f 08), 7. Examiner's	JEFFREY FREDMAN PRIMARY EXAMINER

Application/Control Number: 09/711,476

Art Unit: 1637

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on July 11, 2005 has been entered.

REASONS FOR ALLOWANCE

2. The following is an examiner's statement of reasons for allowance: As before, claim 42 is drawn to an embodiment in which the oligonucleotide array is regenerated by digestion of the newly added nucleotide after completion of the assay. The cited prior art of Soderlund, Goulet, Rust, or Cantor in the IDS, do not teach regeneration of the array by cleavage mechanisms. This claim is novel and unobvious. Claims 54-62, 64 and 65 are drawn to a method in which the single base extension, on an array, uses a series of consecutive primers (often termed a tiled array) as described in claim 54. This description in claim 54 is directly based on figure 1 of the application and also finds support in figure 2 of the Swedish priority document and the description in the specification of the Swedish priority document. The disclosure of the consecutive primers is an inherent theory which uses different words that teach the limitations of claim 54 as per MPEP 2163.02 and 2163.07. None of the cited prior art of Soderlund, Goulet, Rust or Cantor teach or suggest the use of consecutive primers or tiled arrays

Application/Control Number: 09/711,476

Art Unit: 1637

whatsoever. The oldest reference that appears to be combinable with Soderlund and suggests the use of tiled arrays is Chee et al (U.S. Patent 5,861,242), but Chee is not prior art, even if given the earliest priority date, because Chee was filed several days after the Swedish application from which the current application receives benefit.

Further with regard to claim 65, this claim has an additional reason for allowance in that there is no teaching in Soderlund, Southern or Goelet to use dinucleotides, nor in any of the other cited prior art. Soderlund uses two nucleotides sequentially as in figure 3, but never a single dinucleotide molecule for termination.

For these reasons, the claimed invention is novel and unobvious over the cited prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Fredman whose telephone number is (571)272-0742. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571)272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Application/Control Number: 09/711,476 Page 4

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jeffrey Fredman
Primary Examiner

Art Unit 1,637,